Bills · HR 4993
REPORTED· 119TH CONGRESS
House BillHR 4993MedicareHealth care coverage and access
Joe Fiandra Access to Home Infusion Act of 2025
INTRO AUG 19· LAST ACTION DEC 10
READING
2MIN
COSPONSORS
6BIPARTISAN
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Reported, not passed
LEGISLATIVE PROGRESS
STEP 3 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenThis bill matters because it could significantly improve access to critical medical care for many people who need ongoing, complex drug treatments. For patients, being able to receive these infusions at home instead of repeatedly traveling to a clinic or hospital can greatly enhance their quality of life, reduce stress, and minimize exposure to infections in healthcare settings. It addresses a current gap in Medicare coverage where certain necessary home infusion treatments, particularly those requiring professional administration, are not consistently covered.
If this bill becomes law, more Medicare beneficiaries would have the option to receive medically necessary infusion therapy in their homes, potentially making care more convenient and less disruptive to their daily lives. If it doesn't pass, these patients might continue to face high out-of-pocket costs, be forced to receive care in less convenient settings, or even forego necessary treatments due to financial or logistical barriers.
KEY PROVISIONS
3AI-extractedPROVISION 01
Expands Medicare coverage to include external infusion pumps and associated non-self-administrable home infusion drugs that do not currently meet specific durable medical equipment requirements.
This allows patients to receive complex infusion treatments in their homes, improving convenience and access to care that might otherwise be unavailable or require facility-based visits.
PROVISION 02
Establishes criteria for coverage, including that the drug's FDA prescribing information must require professional supervision, a qualified home infusion therapy supplier must administer or supervise the drug, and the drug must be infused at least 12 times per year.
These criteria ensure that only medically necessary and appropriately administered home infusion treatments are covered, maintaining safety and quality standards.
PROVISION 03
Mandates that the Secretary of Health and Human Services notify patients about the cost-sharing differences between home infusion therapy and other settings for infusion drugs.
This provision helps patients make informed decisions about their care by providing transparency regarding their potential out-of-pocket expenses.
SPONSORSHIP
1 + 6
R· Pennsylvania
YRS IN OFFICE
9
BILLS LED
86
COSPONSOR BREAKDOWNBIPARTISAN · 66%
DEM 4 REP 2 IND 0
ACTION TIMELINE
4 EVENTSDEC 10
Committee Consideration and Mark-up Session Held
DEC 10
Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 0.
AUG 19
Introduced in House
AUG 19
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 4993
Congress119th
StatusReported
IntroducedAug 19, 2025
Last actionDec 10, 2025
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
REPORTED· 119TH CONGRESS · ENERGY AND COMMERCE COMMITTEE · INTRODUCED AUG 19, 2025
House BillHR 4993MedicareHealth care coverage and access
Joe Fiandra Access to Home Infusion Act of 2025
INTRODUCED AUG 19, 2025· LAST ACTION DEC 10, 2025
PASSAGE CHANCES
—%
READING
2 min
COSPONSORS
6
COMPLEXITY
Moderate
